Neos Therapeutics is in the healthcare sector and is in the drug manufacturers industry. The company CEO is Gerald McLaughlin. Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.



SeekingAlpha:  Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q1 2019 Results – Earnings Call Transcript

Historical Performance:

Over the last five trading days, NEOS shares returned -15.96% and in the past 30 trading days it returned -29.80%. Over three months, it changed -27.24%. In one year it has changed -76.45% and within that year its 52-week high was 7.75 and its 52-week low was 1.40. NEOS stock is 27.86% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.20 and a 50 day moving average of 2.39. Right now, NEOS stock is trading -44.05% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Neos Therapeutics beats by $0.05, beats on revenue

Liquidity:

The company has a market cap of $89.0m with 49.7m shares outstanding and a float of 47.8m shares. Trading volume was 158,693 shares and has experienced an average volume of 305,647 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Neos Therapeutics was -1.6 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.24.

Base on our calculations, the intrinsic value per share is 44.29, which means it might be undervalued and has a margin of safety of 95.96%

The next earnings report will be: 06-06-2019

The long-term trend of the EPS is an important number as it indicates the present value of Neos Therapeutics; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 26.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 65.80% of institutional ownership.



I calculated the beta to be 1.07

SeekingAlpha:  Neos Therapeutics beats by $0.05, beats on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 3,001.01%, return on assets is -47.01%, profit margin is -83.66%, price-to-sales is 1.73 and price-to-book is 82.87.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here